BriaCell Therapeutics Corp.
Close on Oct 19, 2026
- Market cap
- $24.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Jul 31, 2022 | Oct 28, 2022 | During market hours | – | – | – |
Press releases
Announcements BriaCell Therapeutics filed with the SEC
THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
the three and nine months ended April 30, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Pricing of Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
the three and six months ended January 31, 2026
Regulation FD disclosure · EX-99.2 to Form 8-K
and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $30 million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of US$30 million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
THE THREE MONTH PERIOD ENDED OCTOBER 31, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
the three months ended October 31, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
THE PERIOD ENDED JULY 31, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
the Year Ended July 31, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Proposed Effective Date of Share Consolidation
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $15 million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $15 million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
CONDESED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
Regulation FD disclosure · EX-99.1 to Form 8-K
For the three and nine months ended April 30, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Pricing of $13.8 million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $13.8 million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
the three and six months ended January 31, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Proposed Public Offering of Common Shares
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Therapeutics Announces Closing of Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.3 to Form 8-K
Announces Completion of 15:1 Share Consolidation
Other events · EX-99.1 to Form 8-K
Announces Proposed Effective Date of Share Consolidation
Other events · EX-99.1 to Form 8-K
Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
Other events · EX-99.1 to Form 8-K
THE THREE MONTH PERIOD ENDED OCTOBER 31, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
the three months ended October 31, 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces Proposed Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $5.5 Million Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Therapeutics Announces Closing of $5.5 Million Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.3 to Form 8-K
THE PERIOD ENDED JULY 31, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
the Year Ended July 31, 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
Therapeutics Announces $5 Million Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $5 Million Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor
Other events · EX-99.1 to Form 8-K
Therapeutics Announces $8.5 Million Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Therapeutics Announces Closing of $8.5 Million Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K